US 11,946,938 B2
Circulating Angiopoietin-2 (Ang-2) and insulin-like growth factor-binding protein 7 (IGFBP7) for the prediction of stroke
Ursula-Henrike Wienhues-Thelen, Krailling (DE); Johann Karl, Peissenberg (DE); Peter Kastner, Murnau am Staffelsee (DE); Vinzent Rolny, Munich (DE); Andre Ziegler, Laeufelfingen (CH); and David Conen, Ancaster (CA)
Assigned to Roche Diagnostics Operations, Inc., Indianapolis, IN (US)
Filed by Roche Diagnostics Operations, Inc., Indianapolis, IN (US)
Filed on Jun. 12, 2020, as Appl. No. 16/899,629.
Application 16/899,629 is a continuation of application No. PCT/EP2018/084577, filed on Dec. 12, 2018.
Claims priority of application No. 17207096 (EP), filed on Dec. 13, 2017.
Prior Publication US 2020/0300869 A1, Sep. 24, 2020
Int. Cl. G01N 33/53 (2006.01); G01N 33/68 (2006.01)
CPC G01N 33/6893 (2013.01) [G01N 2333/4745 (2013.01); G01N 2333/515 (2013.01); G01N 2800/326 (2013.01); G01N 2800/50 (2013.01)] 11 Claims
 
1. A method for predicting the risk of stroke of a human subject currently receiving anticoagulation therapy, comprising the steps of
(a) detecting complexes formed by binding of an agent that specifically binds Angiopoietin-2 (Ang-2) and measuring the amount of Angiopoietin-2 (Ang-2) and/or detecting complexes formed by binding of an agent that specifically binds Insulin-like Growth Factor Binding Protein 7 (IGFBP-7) and measuring the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a human subject who suffers from atrial fibrillation, wherein the sample is blood, serum or plasma,
(b) comparing the amount of Ang-2 and/or the amount of IGFBP7 to a reference amount, whereby the risk of stroke is predicted,
(c) identifying a subject as being at elevated risk of stroke when an amount of Ang-2 and/or an amount of IGFBP7 is increased as compared to the reference amount, wherein elevated risk is a risk that is elevated as compared to a subject who has a reduced amount of Ang-2 and/or IGFBP7 as compared to the reference amount, and
(d) administering an intensification of anticoagulation therapy to the subject identified to be at elevated risk to suffer from stroke.